Manufacturer
Sanofi-Aventis Deutschland GmbH
Contents
Lixisenatide
Indication
Adjunct to type 2 diabetes mellitus.
Instruction
Administer via Subcutaneous Injection.
Drug interaction
Increased risk of hypoglycaemia with sulfonylureas or basal insulin. May reduce the rate of absorption of oral medications (e.g. antibiotics, paracetamol, oral contraceptives).
Malaysia
